SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A,
BIB 82.35-4.5%Jan 8 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robohogs who wrote (1869)8/24/2007 11:23:31 PM
From: Jibacoa   of 3722
 
Yes,the Sep issue of BW mentions that ARNA is expected to announce the 6 months safety review of lorcaserin, which is on a PIII for treatment of obesity.
Some analysts say that so far the data have been positive & the drug could be a multi-billion$$ drug & have a 12 month "target" for the stock around $25.(Lorcaserin isn't expected to be selling until 2010.)YHOO's "target" for ARNA is around $20.<g>

businessweek.com

The stock was able to close above the initial resistance of $!3 and the next resistance is now at $13.75 The short position was around 9x its DAV, so there could be some short covering next week.<g>

bigcharts.marketwatch.com

Bernard

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext